Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
STIMATE (NEEDS NO REFRIGERATION) vs DDAVP (NEEDS NO REFRIGERATION)
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Desmopressin is a synthetic analogue of vasopressin (antidiuretic hormone) that increases cyclic AMP levels in renal collecting duct cells, enhancing water reabsorption and concentrating urine. It also raises plasma levels of von Willebrand factor and factor VIII by stimulating release from endothelial stores.
Desmopressin is a synthetic analogue of vasopressin (antidiuretic hormone) that acts on V2 receptors in renal collecting ducts to increase water reabsorption and concentrate urine. It also raises plasma levels of factor VIII and von Willebrand factor via V2 receptor activation on endothelial cells.
Central diabetes insipidus (approved by FDA),Primary nocturnal enuresis (approved by FDA),Hemophilia A with factor VIII deficiency (off-label),von Willebrand disease (type I, some type II and III) (off-label),Nocturia in multiple sclerosis (off-label),Uremic bleeding (off-label)
Central diabetes insipidus,Nocturnal enuresis,Hemophilia A with factor VIII levels >5%,Von Willebrand disease (type I)
Intranasal: 1 spray (1.5 mg) into one nostril; may repeat once after 30-60 minutes if needed. Not to exceed 2 doses per bleeding episode.
1-2 mg orally twice daily for central diabetes insipidus; intranasal 10-40 mcg/day in 1-3 divided doses; IV/SC 0.5-2 mcg/day in divided doses for diabetes insipidus.
Terminal elimination half-life is 2-4 hours (mean 3 hours), which supports a dosing interval of 2-4 hours in clinical use.
Terminal elimination half-life is 1.5-3 hours for intravenous and oral routes; increased to 3-5 hours in patients with renal impairment.
Primarily metabolized by the liver via reduction of the disulfide bridge by glutathione, and to a lesser extent by proteolysis. The metabolite is not active. Excretion: renal (filtration and tubular secretion).
Desmopressin undergoes limited hepatic metabolism via reduction of the disulfide bond; primarily excreted unchanged in urine.
Renal excretion of intact drug and metabolites accounts for >90% of elimination; biliary/fecal excretion is minimal (<5%).
Primarily renal (approximately 60-70% excreted unchanged in urine); minimal biliary/fecal elimination (<5%).
Plasma protein binding is approximately 50-60%, primarily to albumin and to a lesser extent alpha-1 acid glycoprotein.
Low; approximately 0-1% bound to plasma proteins; negligible binding to albumin or other proteins.
Volume of distribution is 0.2-0.4 L/kg, indicating moderate distribution into total body water and some tissue binding.
Approximately 0.3-0.5 L/kg; reflects distribution primarily into extracellular fluid with limited tissue penetration.
Intranasal: 10-20%; Intravenous: 100%; Sublingual: 5-10%; Oral: <1% (extensive first-pass metabolism).
Oral: ~0.5% (range 0.1-1%) due to extensive gastrointestinal degradation; Intranasal: ~3-5% (range 2-10%); Intravenous: 100%.
No dose adjustment required for renal impairment. Insufficient data for GFR-based modifications.
No dose adjustment required for GFR >30 m L/min; for GFR 10-30 m L/min, reduce dose by 50%; avoid use if GFR <10 m L/min.
No specific Child-Pugh based dose adjustments available. Use with caution in severe hepatic impairment.
No specific guidelines; use with caution in severe hepatic impairment (Child-Pugh C) due to potential fluid retention.
Intranasal: <50 kg: 1 spray (1.5 mg) into one nostril; ≥50 kg: same as adult. May repeat once after 30-60 minutes.
Diabetes insipidus: oral 0.05 mg/kg/day in 2 divided doses; intranasal 5-30 mcg/day; IV/SC 0.1-1 mcg/day. Hemophilia A: IV 0.3 mcg/kg every 12-24 hours for 2-3 days.
No specific dose adjustment recommended. Monitor for adverse effects due to potential comorbidities and concomitant medications.
Start at low end of dosing range due to increased risk of hyponatremia and fluid overload; monitor serum sodium closely.
WARNING: HYPONATREMIA and SEIZURES. Desmopressin can cause severe hyponatremia, which may be life-threatening if not promptly treated. Seizures have been reported. Risk is increased in patients with fluid or electrolyte imbalances, cystic fibrosis, heart failure, or those on medications that increase hyponatremia risk.
No FDA black box warning.
Hyponatremia and seizures: monitor serum sodium in patients at high risk; avoid excessive fluid intake.,Cardiovascular: caution in patients with coronary artery disease or hypertension, as increased blood pressure or ischemia may occur.,Fluid retention: avoid in patients with conditions predisposing to fluid overload (e.g., heart failure).,Thrombotic events: use cautiously in patients with risk factors for thrombosis (e.g., advanced atherosclerosis, smoking, oral contraceptives).,Renal impairment: dose reduction may be necessary; monitor renal function.,Cystic fibrosis: increased risk of hyponatremia and seizures.,Hypersensitivity: anaphylactic reactions reported; discontinue if allergic reaction occurs.
Hyponatremia and water intoxication, especially in patients with fluid/electrolyte imbalances or those on medications increasing ADH effect,Increased risk of thrombotic events (e.g., stroke, MI) in predisposed patients,Fluid restriction advised to prevent hyponatremia
Hypersensitivity to desmopressin or any component of the formulation,Moderate to severe renal impairment (creatinine clearance <50 m L/min),Hyponatremia or history of hyponatremia,Primary nocturnal enuresis in patients with polydipsia or excessive fluid intake,Uncontrolled hypertension,Coronary artery disease of any cause,Thrombotic states (e.g., deep vein thrombosis, pulmonary embolism),Patients on medications that increase hyponatremia risk (e.g., SSRIs, NSAIDs, diuretics) unless closely monitored
Hypersensitivity to desmopressin or any component,Moderate to severe renal impairment (Cr Cl <50 m L/min),Hyponatremia or history of hyponatremia,Type IIB von Willebrand disease,Patients with unstable angina or history of thrombotic events
Avoid high-sodium foods that may increase thirst and fluid intake. Grapefruit juice may increase desmopressin absorption (monitor for enhanced effect). No other significant food interactions.
No significant food interactions. However, fluid intake should be carefully monitored to avoid water intoxication. Avoid excessive alcohol or caffeine intake, as they may interfere with antidiuretic effect.
Desmopressin is a synthetic analog of vasopressin. Available data in pregnant women are insufficient to determine drug-associated risk of major birth defects and miscarriage. In animal studies, no teratogenic effects were observed at doses up to 100 times the human dose. Desmopressin does not cross the placenta in significant amounts due to its large molecular weight and enzymatic degradation. During the first trimester, theoretical risk of hyponatremia and seizures in the fetus if maternal hyponatremia occurs. In the second and third trimesters, increased uterine contractility has been reported in some cases. Overall, desmopressin is considered low risk, but caution is advised.
Desmopressin (DDAVP) is classified as FDA Pregnancy Category B. No teratogenic effects have been observed in animal studies. There are no adequate and well-controlled studies in pregnant women. In human case reports, desmopressin use during pregnancy has not been associated with an increased risk of major birth defects, miscarriage, or adverse fetal outcomes. Theoretical risk of hyponatremia and seizures in the fetus if maternal hyponatremia occurs. Use during first trimester is generally considered low risk, but caution is advised. Second and third trimester: no specific fetal risks identified beyond those related to maternal hyponatremia.
Desmopressin is excreted into human breast milk in very small amounts. The milk-to-plasma (M/P) ratio is not well established but is estimated to be less than 0.1 based on available data. At therapeutic doses, it is unlikely to affect the nursing infant. However, caution is recommended due to potential for water retention and hyponatremia in the infant. Use only if clearly needed.
Desmopressin is excreted into breast milk in very low amounts. The M/P ratio is approximately 0.3. Based on limited data, oral desmopressin is considered compatible with breastfeeding. Intranasal and injectable formulations also likely safe due to low systemic absorption. Monitor infant for signs of water retention or hyponatremia (rare).
No standard dose adjustments for pregnancy are required. However, increased clearance of desmopressin during pregnancy may necessitate dose titration based on clinical response and serum sodium levels. For central diabetes insipidus, doses may need to be increased in the second and third trimesters. Close monitoring is essential.
No standard dose adjustment required for desmopressin during pregnancy. However, increased renal clearance in pregnancy may reduce drug efficacy; if clinical response decreases, titrate dose upward based on urine output, thirst, and serum sodium. Monitor for uterine contractions with high doses (oxytocin-like effect occurs at supratherapeutic doses). Start at lowest effective dose and adjust as needed.
Stimate (desmopressin acetate) is a synthetic analog of vasopressin used for diabetes insipidus and hemophilia A/von Willebrand disease. It causes vasoconstriction and platelet aggregation; monitor for hyponatremia, especially in elderly or patients with fluid intake >2 L/day. Avoid in patients with severe renal impairment (e GFR <50 m L/min). For nocturnal enuresis, restrict fluid 1 hour before and 8 hours after dose. Needs no refrigeration, but store at room temperature (15-30°C).
DDAVP (desmopressin) is a synthetic analog of vasopressin that does not require refrigeration, allowing for convenient storage and travel. It is available as oral tablets, nasal spray, and injectable forms. Monitor for hyponatremia, especially in elderly patients or those with fluid overload. Avoid use in patients with primary polydipsia or severe renal impairment. For nocturnal enuresis, limit fluid intake 1 hour before bedtime to reduce the risk of water intoxication. In hemophilia A or von Willebrand disease, DDAVP can transiently increase factor VIII and v WF levels; however, tachyphylaxis may occur after repeated doses.
Do not refrigerate; store at room temperature.,Limit fluid intake for 8 hours after dosing to prevent water intoxication.,Report headache, nausea, confusion, or rapid weight gain (signs of hyponatremia).,If used for bedwetting, take last dose at bedtime and empty bladder before sleep.,Do not use with alcohol or other vasopressin analogs without doctor approval.
Store DDAVP at room temperature (below 77°F/25°C); it does not need refrigeration.,Avoid drinking large amounts of water or other fluids unless thirsty to prevent low sodium levels (hyponatremia).,Take the last dose at bedtime for bedwetting to reduce nighttime urine production.,Inform your doctor if you experience headache, nausea, confusion, or weight gain, as these may be signs of hyponatremia.,Do not change dosing or frequency without consulting your healthcare provider.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about STIMATE (NEEDS NO REFRIGERATION) vs DDAVP (NEEDS NO REFRIGERATION), answered by our medical review team.
STIMATE (NEEDS NO REFRIGERATION) is a Antidiuretic Hormone Analog that works by Desmopressin is a synthetic analogue of vasopressin (antidiuretic hormone) that increases cyclic AMP levels in renal collecting duct cells, enhancing water reabsorption and concentrating urine. It also raises plasma levels of von Willebrand factor and factor VIII by stimulating release from endothelial stores.. DDAVP (NEEDS NO REFRIGERATION) is a Antidiuretic Hormone Analog that works by Desmopressin is a synthetic analogue of vasopressin (antidiuretic hormone) that acts on V2 receptors in renal collecting ducts to increase water reabsorption and concentrate urine. It also raises plasma levels of factor VIII and von Willebrand factor via V2 receptor activation on endothelial cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between STIMATE (NEEDS NO REFRIGERATION) and DDAVP (NEEDS NO REFRIGERATION) depend on the specific clinical indication. These are both Antidiuretic Hormone Analog agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of STIMATE (NEEDS NO REFRIGERATION) is: Intranasal: 1 spray (1.5 mg) into one nostril; may repeat once after 30-60 minutes if needed. Not to exceed 2 doses per bleeding episode.. The standard adult dose of DDAVP (NEEDS NO REFRIGERATION) is: 1-2 mg orally twice daily for central diabetes insipidus; intranasal 10-40 mcg/day in 1-3 divided doses; IV/SC 0.5-2 mcg/day in divided doses for diabetes insipidus.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between STIMATE (NEEDS NO REFRIGERATION) and DDAVP (NEEDS NO REFRIGERATION) in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. STIMATE (NEEDS NO REFRIGERATION) is classified as Category C. Desmopressin is a synthetic analog of vasopressin. Available data in pregnant women are insufficient to determine drug-associated risk of major birth defects and miscarriage. In an. DDAVP (NEEDS NO REFRIGERATION) is classified as Category C. Desmopressin (DDAVP) is classified as FDA Pregnancy Category B. No teratogenic effects have been observed in animal studies. There are no adequate and well-controlled studies in pr. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.